Skip to main content
Aarti Pharmalabs Limited logo

Aarti Pharmalabs Limited — Investor Relations & Filings

Ticker · AARTIPHARM ISIN · INE0LRU01027 LEI · 335800TTAKRBNDK5P363 BSE.NS Manufacturing
Open in API
Filings indexed 246 across all filing types
Latest filing 2025-07-09 Regulatory Filings
Country IN India
Listing BSE.NS AARTIPHARM

About Aarti Pharmalabs Limited

https://www.aartipharmalabs.com/

Aarti Pharmalabs Limited is a manufacturer of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and xanthine derivatives. The company specializes in the development and production of complex chemistry-based products for the global pharmaceutical and generic drug industries. Its core portfolio includes APIs across diverse therapeutic areas such as oncology, cardiovascular, and anti-diabetics. Additionally, the company is a major producer of xanthines, including caffeine and theophylline. Aarti Pharmalabs offers comprehensive Contract Development and Manufacturing Organization (CDMO) services, leveraging its integrated research and development capabilities and large-scale manufacturing facilities. The organization maintains high regulatory standards, ensuring compliance with international quality benchmarks to serve a global clientele.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialisation activities for the quarter ended June 30, 2025. It is addressed to stock exchanges and signed by the company secretary and the registrar and share transfer agent. The document is short (3004 characters) and serves as a compliance certificate rather than a financial report or detailed filing. It does not contain financial statements or management discussion but is a regulatory compliance certificate. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and not a full report or announcement of a report.
2025-07-09 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2025-07-03 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the closure of the trading window in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. It announces the period during which insiders are prohibited from trading due to upcoming financial results. The document does not contain any financial data, results, or detailed report content. It is a regulatory announcement related to insider trading compliance and timing of financial results disclosure, not the financial results or report itself. The document length is short (1565 characters), and it serves as a notification to the exchanges and public about trading restrictions. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-06-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the intimation of an upcoming earnings conference call scheduled for June 24 and 25, 2025. It references Regulation 30 of SEBI (LODR) Regulations 2015, which governs disclosure obligations. The content is an announcement of the schedule for analyst/institutional investor meetings and explicitly states that no unpublished price-sensitive information will be disclosed. The document length is short (1662 characters) and does not contain any financial data or results itself, only the notification of the call. Therefore, this is not the earnings release or the call transcript but an announcement about the earnings call event. According to the filing definitions, this fits best under Call Transcript (CT) category as it relates to the earnings conference call, but since it is only an intimation of the call schedule and not the transcript itself, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a regulatory announcement about the call schedule without substantive financial content or transcript text.
2025-06-18 English
Updates
Regulatory Filings
2025-05-27 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of the Q4 and full year FY25 earnings conference call for Aarti Pharmalabs Limited, dated May 16, 2025. It includes management's opening remarks, financial highlights, business segment performance, growth initiatives, sustainability achievements, and a forward outlook. The text also contains a Q&A session with analysts discussing business specifics. The presence of detailed financial data, management commentary, and Q&A indicates this is a full transcript of an earnings call rather than a brief earnings release or a simple announcement. The document references the audited financial results for Q4/H2 FY25 and discusses them in detail. Therefore, the document fits the definition of a Call Transcript (CT).
2025-05-16 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.